Graham Lumsden
Chief Executive Officer chez BioMarck Pharmaceuticals Ltd.
Profil
Graham George Lumsden is currently the President & Chief Executive Officer at BioMarck Pharmaceuticals Ltd.
and a Member at the Royal College of Veterinary Surgeons.
He previously served as the Chief Executive Officer & Executive Director at Motif BioSciences, Inc., Chief Executive Officer at Tiemed LLC, Director at Immutep Ltd., Non-Executive Director at Motif Bio Plc, and Principal at Merck & Co., Inc. and Carnethy Consulting LLC.
Lumsden received his undergraduate degree from The Royal School of Veterinary Studies in 1982.
Postes actifs de Graham Lumsden
| Sociétés | Poste | Début |
|---|---|---|
Royal College of Veterinary Surgeons
 Royal College of Veterinary Surgeons Miscellaneous Commercial ServicesCommercial Services The Royal College of Veterinary Surgeons is an organization that provides information on the outcomes of disciplinary hearings against veterinarians and registered veterinary nurses. The information includes announcements, charges, findings, reasons, decisions, judgments, and press releases. | Corporate Officer/Principal | - |
BioMarck Pharmaceuticals Ltd.
 BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Chief Executive Officer | 05/01/2021 |
Anciens postes connus de Graham Lumsden
| Sociétés | Poste | Fin |
|---|---|---|
| MOTIF BIO PLC | Chief Executive Officer | 04/05/2020 |
| Tiemed LLC | Chief Executive Officer | 01/01/2014 |
| Carnethy Consulting LLC | Corporate Officer/Principal | 01/01/2014 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2001 |
| IMMUTEP LIMITED | Director/Board Member | - |
Formation de Graham Lumsden
| The Royal School of Veterinary Studies | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMMUTEP LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
Motif BioSciences, Inc.
 Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY. | Health Technology |
BioMarck Pharmaceuticals Ltd.
BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Health Technology |
Royal College of Veterinary Surgeons
Royal College of Veterinary Surgeons Miscellaneous Commercial ServicesCommercial Services The Royal College of Veterinary Surgeons is an organization that provides information on the outcomes of disciplinary hearings against veterinarians and registered veterinary nurses. The information includes announcements, charges, findings, reasons, decisions, judgments, and press releases. | Commercial Services |
| Tiemed LLC | |
| Carnethy Consulting LLC | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
